US20190381147A1 - Pharmaceutical composition containing insulin-like growth factor-2 and use thereof - Google Patents
Pharmaceutical composition containing insulin-like growth factor-2 and use thereof Download PDFInfo
- Publication number
- US20190381147A1 US20190381147A1 US16/464,902 US201716464902A US2019381147A1 US 20190381147 A1 US20190381147 A1 US 20190381147A1 US 201716464902 A US201716464902 A US 201716464902A US 2019381147 A1 US2019381147 A1 US 2019381147A1
- Authority
- US
- United States
- Prior art keywords
- igf
- macrophages
- macrophage
- insulin
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 title claims abstract description 157
- 102100025947 Insulin-like growth factor II Human genes 0.000 title claims abstract description 157
- 229940068935 insulin-like growth factor 2 Drugs 0.000 title claims abstract description 157
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 52
- 210000002540 macrophage Anatomy 0.000 claims abstract description 220
- 230000014509 gene expression Effects 0.000 claims abstract description 65
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract description 42
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 42
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 22
- 230000001737 promoting effect Effects 0.000 claims abstract description 14
- 201000002491 encephalomyelitis Diseases 0.000 claims description 42
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 40
- 208000023275 Autoimmune disease Diseases 0.000 claims description 34
- 230000004069 differentiation Effects 0.000 claims description 27
- 239000002516 radical scavenger Substances 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 210000003289 regulatory T cell Anatomy 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 230000010627 oxidative phosphorylation Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 11
- 230000005012 migration Effects 0.000 claims description 10
- 238000013508 migration Methods 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 8
- 239000002502 liposome Substances 0.000 claims description 8
- 206010022489 Insulin Resistance Diseases 0.000 claims description 7
- 210000000447 Th1 cell Anatomy 0.000 claims description 7
- 210000000068 Th17 cell Anatomy 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 230000037353 metabolic pathway Effects 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 230000001363 autoimmune Effects 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 229960000579 clodronate disodium Drugs 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 229940122862 PD-L1 agonist Drugs 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 17
- 241000699670 Mus sp. Species 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 24
- 210000001072 colon Anatomy 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 15
- 229920006008 lipopolysaccharide Polymers 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 210000003024 peritoneal macrophage Anatomy 0.000 description 10
- 210000000278 spinal cord Anatomy 0.000 description 10
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000001506 immunosuppresive effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 6
- 102100022338 Integrin alpha-M Human genes 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 229960002286 clodronic acid Drugs 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 108010081690 Pertussis Toxin Proteins 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000008672 reprogramming Effects 0.000 description 5
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 4
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 4
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 4
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 4
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 229920003045 dextran sodium sulfate Polymers 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229930191479 oligomycin Natural products 0.000 description 4
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002608 insulinlike Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- -1 (c1) optionally Substances 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006536 aerobic glycolysis Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 1
- 206010057669 Colon injury Diseases 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Definitions
- This invention relates to the field of biological medicine, and in particular to a pharmaceutical composition containing insulin-like growth factor-2 and use thereof.
- Macrophages are specialized immune cells distributed in all parts of the body. They remove the senescence cells, certain cells that cannot be recognized as their own, cell debris and so on through phagocytosis. As the professional antigen presenting cells, macrophages initiate the immune responses of unsensitized T cells and trigger the inflammatory response. However, inflammatory cytokines expressed by macrophages such as TNF ⁇ and IL-1 also play important roles in the pathogenesis of many autoimmune diseases. Removal of pathogenic macrophages has been shown to significantly inhibit autoimmune encephalomyelitis and inflammatory bowel diseases.
- macrophages can be regulated by different circumstances factors into cells with immunosuppressive effect, such as macrophages marked by expressing IL-1 ⁇ , Arginase I, etc, as well as macrophages with immunosuppressive function which are formed by different immune stimuli in the evolution process of monocytes to macrophages, thereby directly or indirectly regulating the body's immune response. It has been reported that spermidine treated macrophages are able to powerfully treat autoimmune diseases, indicating that macrophages with immunosuppressive effect have significant therapeutic effects in autoimmune diseases.
- the present invention provides a composition containing insulin-like growth factor-2 and the uses thereof.
- the first aspect of the invention provides a use of insulin-like growth factor-2 (IGF-2) to prepare a composition (including a chemical preparation and a pharmaceutical composition) to (i) increase PD-L1 expression in macrophage and/or (ii) inhibit IL-1 ⁇ expression in macrophage.
- IGF-2 insulin-like growth factor-2
- the IGF-2 includes full length IGF-2 and an active fragment of IGF-2.
- the active fragment of IGF-2 is an active fragment having amino acids from position 25 to position 91 of IGF-2.
- the active fragment of IGF-2 is the amino acid sequence of position 25 to position 91 of IGF-2.
- the IGF-2 is from human and non-human mammals.
- amino acid sequence of the IGF-2 is shown in SEQ ID NO.:1.
- the pharmaceutical composition is also used for one or more of the purposes selected from the group consisting of:
- the autoimmune disease is selected from the group consisting of multiple sclerosis, inflammatory bowel disease, autoimmune encephalomyelitis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, insulin resistance, diabetes, liver cirrhosis or a combination thereof.
- the insulin resistance or the diabetes is obesity-induced insulin resistance or obesity-induced diabetes.
- the pharmaceutical composition comprises (a) IGF-2; and (b) a pharmaceutically acceptable carrier.
- the pharmaceutical composition comprises 0.001-99 wt %, preferred 0.1-90 wt %, and more preferred 1-80% IGF-2, based on the total weight of the pharmaceutical composition.
- the pharmaceutical composition comprises macrophage scavenger, and the scavenger is a formulation for removing macrophage or inhibiting macrophage migration.
- the pharmaceutical composition comprises agonist of PD-L1.
- the pharmaceutical composition is liquid or lyophilized formulation.
- the pharmaceutical composition is an injection formulation.
- the second aspect of the invention provides a use of macrophage treated with insulin-like growth factor-2 (IGF-2) for preparing a pharmaceutical composition for one or more of the purposes selected from the group consisting of:
- IGF-2 insulin-like growth factor-2
- macrophage is cultured in the presence of IGF-2 to obtain the macrophage treated with the IGF-2.
- the third aspect of the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising (a) IGF-2 or the active fragment thereof (such as active fragment having amino acids from position 25 to position 91), (b) optionally, macrophage scavenger, (c) optionally, PD-L1 promoter, and (d) a pharmaceutically acceptable carrier.
- At least one of the components (b) and (c) is present.
- the macrophage scavenger is an agent for removing macrophage or inhibiting macrophage migration.
- the formulation of the pharmaceutical composition is an injection formulation, sustained release formulation or topical formulation.
- the pharmaceutical composition is used for one or more of the purposes selected from the group consisting of:
- the pharmaceutical composition comprises macrophage scavenger which depletes macrophage or suppresses macrophage migration.
- the macrophage scavenger is selected from the group consisting of: CCR2 inhibitor (to inhibit macrophage migration), clodronate disodium liposome (to remove macrophage) and a combination thereof.
- the pharmaceutical composition comprises component (a), component (b) and component (c)
- the mass ratio of component (a): component (b): component (c) is (1-100): (1-100): (1-100).
- the pharmaceutical composition comprises component (a) and component (b)
- the mass ratio of component (a): component (b) is (1-100): (1-100).
- the pharmaceutical composition comprises component (a) and component (c)
- the mass ratio of component (a): component (c) is (1-100): (1-100).
- the ratio (mg: mg) of IGF-2 active fragment having amino acids from position 25 to position 91 to macrophage scavenger ranges from 1:100 to 100:1, preferably, from 1:20 to 20:1.
- the total content of IGF-2 active fragment having amino acids from position 25 to position 91 and macrophage scavenger is 1 to 99 wt % of the pharmaceutical composition, preferably, 5 to 90wt % of the total pharmaceutical composition.
- the fourth aspect of the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising (a1) IGF-2 inhibitor, (b1) optionally, macrophage agonist, (c1) optionally, PD-L1 inhibitor, and (d1) a pharmaceutically acceptable carrier.
- At least one of the components (b1) and (c1) is present.
- the PD-L1 inhibitor includes PD-L1 antibodies.
- the pharmaceutical composition comprises component (a1), component (b1) and component (c1)
- the mass ratio of component (a1): component (b1): component (c1) is (1-100): (1-100): (1-100).
- the pharmaceutical composition comprises component (a1) and component (b1)
- the mass ratio of component (a1): component (b1) is (1-100): (1-100).
- the pharmaceutical composition comprises component (a1) and component (c1)
- the mass ratio of component (a1): component (c1) is (1-100): (1-100).
- the fifth aspect of the invention provides a macrophage pre-treated with IGF-2.
- the PD-L1 expression is up-regulated and/or (ii) the IL-1 ⁇ expression is down-regulated.
- the up-regulation referred to that the ratio of PD-L1 expression quantity in treated macrophage (M1) to PD-L1 expression quantity in untreated macrophage (M0) M1/M0 is ⁇ 1.5, preferably, M1/M0 ⁇ 2.0, more preferably, M 1/M0 ⁇ 3.0.
- the down-regulation referred to that the ratio of IL-1 ⁇ expression quantity in untreated macrophage (N0) to IL-1 ⁇ expression quantity in treated macrophage (N1) N0/N1 is ⁇ 1.5, preferably, N0/N1 ⁇ 2.0, more preferably, N0/N1 ⁇ 3.0.
- the treatment includes exposing macrophage to IGF-2 or IGF-2 active fragment for a period of time (such as 0.1-24 hours).
- the sixth aspect of the invention provides a pharmaceutical composition for regulating T cell differentiation, which comprises IGF-2 treated macrophage and a pharmaceutically acceptable carrier.
- the regulating T cell differentiation referred to (b) promoting differentiation of regulatory T cell; and/or (c) inhibiting differentiation of Th1 and/or Th17 cell.
- the pharmaceutical composition is used for treating autoimmune disease.
- the seventh aspect of the invention provides a non-therapeutic method for (i) promoting PD-L1 expression and/or (ii) inhibiting IL-1 ⁇ expression in macrophage, which comprises the following steps:
- the concentration of IGF-2 is 1 ng/ml-100 ⁇ g/ml, preferably, 3 ng/ml-1 ⁇ g/ml, and more preferably, 5 ng/ml-50 ng/ml.
- the eighth aspect of the invention provides a polypeptide with a sequence of position 25 to position 91 of SEQ ID NO.: 1.
- the ninth aspect of the invention provides a method for (i) enhancing PD-L1 expression and/or (ii) inhibiting IL-1 ⁇ expression, which comprises the following steps:
- the subject includes human and nonhuman mammal.
- the dose of IGF-2 administered is 1 ng-1 mg/kg, preferably, 100 ng-100 ⁇ g/kg, and more preferably, 1-10 ⁇ g/kg.
- the method further comprises the steps of:
- macrophage scavenger which is an agent for removing macrophage or inhibiting macrophage migration
- the dose and frequency of macrophage scavenger are administered in a conventional manner.
- the administration includes administrating simultaneously or successively.
- the tenth aspect of the invention provides a medicine kit, which contains:
- a first container which contains an active ingredient (a) IGF-2 or a medicine containing the active ingredient (a);
- a second container which contains an active ingredients
- macrophage scavenger or a medicine containing the active ingredient (b)
- the macrophage scavenger is an agent for removing macrophage or inhibiting macrophage migration
- the medicine in the first container or the second container is a formulation containing one single active ingredient (a) or a formulation containing one single active ingredient (b).
- the eleventh aspect of the invention provides a use of the pharmaceutical composition in the third aspect and the medicine kit in the tenth aspect in preparation of a medicine for treating an autoimmune disease.
- FIG. 1 shows that insulin-like growth factor 2 (IGF-2) is effective in treating EAE.
- IGF-2 insulin-like growth factor 2
- FIG. 1 a shows that IGF-2 can effectively alleviate the progress and degree of EAE.
- FIG. 1 b shows that IGF-2 can effectively inhibit mononuclear cell infiltration in the central nervous system.
- FIG. 1 c shows that IGF-2 can effectively inhibit MOG specific T cell proliferation in EAE mice.
- FIG. 1 d , 1 e , 1 f , and 1 g show that IGF-2 can effectively inhibit the cell proportion of Th1 and Th17 in EAE mice and promote the proportion of Treg.
- FIG. 1 h shows that IGF-2 does not directly effect the differentiation of Th1/Th17/Treg.
- FIG. 1 i and 1 j show that IGF-2 promotes PD-L1 expression and inhibits IL-1 ⁇ expression in the CD11b+F4/80+ macrophage in the spinal cord of EAE mice.
- FIG. 2 shows that insulin-like growth factor-2 (IGF-2) can induce anti-inflammatory macrophages.
- IGF-2 insulin-like growth factor-2
- FIG. 2 a shows that IGF-2 does not affect the number of macrophages in the spinal cord of EAE mice.
- FIG. 2 b shows that IGF-2 does not affect the number of macrophages in the spleen of EAE mice.
- FIG. 2 c shows that IGF-2 inhibits the expression level of IL-1 ⁇ in CD11b+F4/80+ macrophages in the spleen of EAE mice.
- FIG. 2 d shows that IGF-2 promotes the expression level of PD-L1 in CD11b+F4/80+ macrophages in the spinal cord of EAE mice.
- FIG. 2 e shows that IGF-2 does not affect the expression levels of MHC-I, MHC-II, CD80, and CD86 in thioglycollate medium-induced peritoneal macrophages.
- FIG. 2 f shows that IGF-2 does not affect the expression levels of TNF- ⁇ , IL-6 and TGF- ⁇ in peritoneal macrophages under lipopolysaccharide (LPS) stimulation and thioglycollate medium-induction.
- LPS lipopolysaccharide
- FIG. 2 g shows that IGF-2 inhibits the mRNA levels of inducible nitric oxide synthase (iNOS) and the production of nitrite regulated by the enzyme, in the peritoneal macrophages under lipopolysaccharide (LPS) stimulation and thioglycollate medium-induction.
- iNOS inducible nitric oxide synthase
- LPS lipopolysaccharide
- FIG. 3 shows that insulin-like growth factor-2 (IGF-2) treated macrophages are effective in treating EAE.
- IGF-2 insulin-like growth factor-2
- FIG. 3 a shows that after IGF-2 pretreatment, under 100 ng/ml LPS stimulation, the ability of peritoneal macrophages induced by thioglycollate medium to express messenger RNA and precursor proteins of IL-1 ⁇ is significantly decreased.
- FIG. 3 b shows that after IGF-2 pretreatment, under 100 ng/ml LPS stimulation, the IL-1 ⁇ protein level secreted by peritoneal macrophages induced by thioglycollate medium is significantly decreased.
- FIG. 3 c shows that after IGF-2 pretreatment, under 100 ng/ml LPS stimulation, the PD-L1 protein level expressed by peritoneal macrophages induced by thioglycollate medium is significantly increased.
- FIGS. 3 d and 3 e show that IGF-2 treated macrophages are able to promote Treg differentiation depend on PD-L1.
- FIG. 3 f shows that IGF-2 treated macrophages significantly inhibits EAE.
- FIG. 3 g shows that IGF-2 treated macrophages can effectively promote the proportion of Tregs in EAE mice.
- FIG. 4 shows that bone marrow derived macrophages treated with insulin-like growth factor-2 (IGF-2) to promote the differentiation ability of regulatory T cell.
- IGF-2 insulin-like growth factor-2
- FIG. 4 a shows that bone marrow derived macrophages treated with IGF-2 express significant higher level of PD-L1 under LPS stimulation.
- FIGS. 4 b and 4 c show that bone marrow derived macrophages treated with IGF-2 promote Treg through PD-L1.
- FIG. 4 d shows no change in the expression levels of MHC-I, MHC-II, CD80, and CD86 in bone marrow derived macrophages treated with IGF-2.
- FIG. 5 shows that bone marrow derived macrophages treated with insulin-like growth factor-2 (IGF-2) are effectively in alleviating experimental autoimmune encephalomyelitis (EAE) and inflammatory bowel disease (IBD).
- IGF-2 insulin-like growth factor-2
- FIG. 5 a shows that bone marrow derived macrophages treated with IGF-2 are effective in treating EAE.
- FIGS. 5 b and 5 c show that bone marrow derived macrophages treated with IGF-2 effectively increase the proportion of Treg in EAE mice.
- FIG. 5 d shows that bone marrow derived macrophages treated with IGF-2 relieved weight loss in IBD mice. Macrophages treated with IGF-2 shows the ability to effectively treat IBD.
- FIG. 5 e shows that bone marrow derived macrophages treated with IGF-2 can effectively prolong the survival time of mice with IBD.
- FIGS. 5 f and 5 g show that bone marrow derived macrophages treated with IGF-2 effectively increase the proportion of Treg cells in spleen in the IBD mice.
- FIG. 6 shows that insulin-like factor-2 (IGF-2) affects the anti-inflammatory prosperities of macrophages through regulating their glycometabolism.
- IGF-2 insulin-like factor-2
- FIG. 6 a shows that glucose consumption was significantly reduced in macrophages after IGF-2 treated.
- FIG. 6 b shows that lactic acid accumulation was significantly reduced in macrophages after IGF-2 treated.
- FIG. 6 c shows that NAD+/NADH ratio was significantly reduced in macrophages after IGF-2 treated.
- FIG. 6 d shows that the ability of oxidative phosphorylation and oxygen consumption was significantly increased in macrophages after IGF-2 treated.
- FIG. 6 e shows that extracellular acidification was significantly reduced in macrophages after IGF-2 treated.
- FIG. 6 f shows that macrophages preferred to conduct oxidative phosphorylation after IGF-2 treated.
- FIG. 6 g shows that oligomycin could inhibit the improvement of PD-L1 expression in peritoneal macrophages treated with IGF-2 and induced by thioglycollate medium.
- FIG. 6 h shows that oligomycin inhibits oxidative phosphorylation, and demonstrates that macrophages treated with IGF-2 have high expression of PD-L1 depended on aerobic respiration and the ability to promote the production of Treg.
- FIG. 7 shows that insulin-like growth facor-2 (IGF-2) and IGF-2 treated macrophages are effective in treating experimental bowel disease.
- IGF-2 insulin-like growth facor-2
- FIG. 7 a shows that IGF-2 protects IBD mice from body weight loss.
- FIG. 7 b shows that IBD mice received IGF-2 treatment have significant longer colon length.
- FIG. 7 c shows that numbers of mononuclear cells infiltration significantly decrease in colon after IGF-2 treatment.
- FIGS. 7 d and 7 e show that the proportion of Treg cells in the lamina intestinal of colon significantly increase in the IBD mice after IGF-2 treatment.
- FIG. 7 f shows that the expression of PD-L1 significantly increases in CD11b+F4/80+ macrophages in the lamina intestinal of the IBD mice after IGF-2 treatment.
- FIG. 7 g shows that the expression level of IL-1 ⁇ significantly decrease in CD11b+F4/80+ macrophages in the lamina intestinal of the IBD mice after IGF-2 treatment.
- FIG. 7 h shows that IGF-2 treated macrophage relieves the body weight loss of experimental bowel disease mice.
- FIG. 7 i shows that IGF-2 treated macrophage effectively prolongs the survival time of the IBD mice.
- FIG. 7 j shows that the proportion of Treg cells in spleen significantly increase in the IBD mice injected with IGF-2 treated macrophage.
- FIG. 8 shows that insulin-like growth factor-2 (IGF-2) regulates immune response in the spleen and peritoneal lymph nodes of inflammatory bowel disease (IBD) mice.
- IGF-2 insulin-like growth factor-2
- FIGS. 8 a and 8 b show that IGF-2 significantly up regulates the proportion of Tregs in the peritoneal lymph nodes of mice with IBD.
- FIG. 8 c shows that IGF-2 does not affect the proportion of spleen macrophages in mice with IBD.
- FIG. 8 d shows that IGF-2 upregulates the proportion of CD11b+F4/80+ macrophages in the colon lamina intestinal of mice with IBD.
- FIG. 8 e shows that IGF-2 significantly downregulates the expression level of IL-1 ⁇ in spleen macrophages in mice with IBD.
- FIG. 8 f shows that IGF-2 significantly up regulates the expression level of PD-L1 in spleen macrophages in mice with IBD.
- FIG. 9 shows that peritoneal macrophages treated with insulin-like growth factor-2 (IGF-2) and induced by thioglycollate medium can upregulate Tregs in lamina intestinal of colon and peritoneal lymph nodes of IBD mice.
- IGF-2 insulin-like growth factor-2
- FIG. 9 a shows that IGF-2 treated macrophages can significantly increase the proportion of Tregs in peritoneal lymph nodes of IBD mice.
- FIG. 9 b shows that IGF-2 pre-treated macrophages can significantly increase the proportion of Tregs in lamina intestinal of colon of IBD mice.
- FIG. 10 shows that separate injection of insulin-like growth factor-2 (IGF-2) and clodronate liposome can significantly inhibit the progress of EAE and play an effective therapeutic role when compared with that of control mice group. Importantly, combined injection of IGF-2 and clodronate liposome has significantly better therapeutic effects on EAE than other groups.
- IGF-2 insulin-like growth factor-2
- clodronate liposome has significantly better therapeutic effects on EAE than other groups.
- FIG. 11 shows the tertiary structure of insulin-like growth factor-2 (IGF-2).
- FIG. 12 shows the key binding sites of insulin-like growth factor-2 (IGF-2) to the receptor.
- IGF-2 insulin-like growth factor-2
- FIG. 13A shows the results of glucose tolerance test.
- FIG. 13B shows the results of insulin tolerance test.
- IGF-2 applied in the reference and description of FIGS. 1-13 is active fragment of IGF-2 containing amino acids from position 25 to position 91. (IGF 25-91 )
- the inventors After extensive and thorough studies, the inventors have firstly established a pharmaceutical composition containing insulin-like growth factor-2 and use thereof.
- This invention provides the use of IGF-2 and its active fragment for preparing a pharmaceutical composition.
- the pharmaceutical composition can be used for (i) enhancing PD-L1 expression and/or (ii) inhibiting IL-1 ⁇ expression in macrophages.
- the invention also provides a pharmaceutical composition containing insulin-like growth factor-2 as an active ingredient.
- IGF-2 insulin-like growth factor-2
- IGF 25-91 insulin-like growth factor-2
- IGF 25-91 insulin-like growth factor-2
- IGF 25-91 insulin-like growth factor-2
- IGF 25-91 insulin-like growth factor-2
- IGF 25-91 the active fragment having amino acids from position 25 to position 91 of IGF-2
- IGF 25-91 indirectly upregulates regulatory T cells (Treg) by inducing macrophages with low IL-1 expression and high PD-L1 expression, thereby promoting the recovery of autoimmune diseases.
- IGF 25-91 mainly promotes the reprogramming of macrophages into macrophages with immunosuppressive function by affecting the aerobic glycolysis and oxidative phosphorylation pathways of macrophages, and such macrophages treated with IGF 25-91 have a very significant effect on the treatment of autoimmune diseases.
- the present invention clarifies the regulatory mechanism of IGF 25-91 on macrophages, and it is found that IGF 25-91 induces the application potential of macrophages with immunosuppressive function in the treatment of autoimmune diseases, thus forming a new technique for macrophage immunotherapy.
- IGF-2 Insulin-like growth factor-2
- IGF-2 precursor protein which is translated from mRNA, consists of 180 amino acids, as shown in the sequence SEQ ID NO.: 1 (mgipmgksmlvlltflafascciaayrpset lcggelvdtlqfvcgdrgfyfsrpasrvsrrsrgiveeccfrscdlalletycatpakserdvstpptvlpdnfprypvgkffqydtwkqst qrlrrglpallrarrghvlakeleafreakrhrplialptqdpahggappemasnrk);
- the active form produced after modification after translation consists of 67 amino acids, as shown in the sequence SEQ ID NO.: 1 (mgipmgksmlvlltflafascciaayrpset lcggelvdtlqfv
- the tertiary structure of IGF-2 is composed of three ⁇ -helixes and two ⁇ -sheets as shown in FIG. 11 , wherein amino acids 11G-21C forms a helix, 25G-27Y forms the first sheet, the second helix is 42I-49R, the third helix is 53L-58T and the second sheet is 59Y-61A. It is predicted that T16 and F19 on the first helix and L63 on the third helix are sites where IGF-2 binds to receptor of IGF-2 as shown in FIG. 12 .
- IGF-2 has an important role in embryo development and can promote embryo development and organ formation. It has also been reported to be linked to memory and reproduction, and studies in genetically deficient mice have shown that lack of insulin-like growth factor-2 signaling can lead to poor brain development.
- the present invention has found that administration of IGF-2 or active fragment having the amino acids sequence from position 25 to position 91 of IGF-2 (IGF 25-91 ) alone can effectively treat experimental autoimmune encephalomyelitis or inflammatory bowel disease, which are two autoimmune diseases.
- IGF 25-91 IGF 25-91
- the proportion of regulatory T cells in the IGF 25-91 treatment group was significantly increased, and the proportions of TH1 and TH17 cells were significantly decreased.
- IGF 25-91 could not directly affect the efficiency of T cell differentiation into Th1, Th17 and Treg.
- IGF 25-91 has an indirect effect on the proportion change of T cell subsets.
- Significant changes in the macrophage phenotype were also observed when insulin-like growth factor-2 was used to treat autoimmune diseases. It was found in the study that the expression of IL-1 ⁇ in macrophages at the injury site of mice treated with IGF 25-91 was significantly decreased, while the expression of PD-L1 was significantly increased, suggesting that IGF 25-91 played a role in inhibiting autoimmune diseases through promoting the proportion of macrophages with anti-inflammatory effects.
- IGF 25-91 does not directly induce the expression of anti-inflammatory genes in macrophages.
- the bone marrow or enterocoelia derived mature macrophages treated with IGF 25-91 exhibit significantly decrease of IL-1 ⁇ expression and significantly increase of PD-L1 expression in response to lipopolysaccharide stimulation.
- Macrophages play an important role in the occurrence and development of autoimmune diseases.
- a series of studies have shown that macrophages can exert strong proinflammatory ability under the stimulation of inflammatory factors such as interferon and lipopolysaccharide, which aggravate the process of autoimmune diseases.
- IGF 25-91 insulin-like growth factor-2 alters the response of macrophages to inflammatory factors, and macrophages overexpress the anti-inflammatory molecule PD-L1 under the condition of proinflammatory stimulation. Therefore, the treatment of autoimmune diseases by IGF 25-91 is likely to be achieved by reprogramming macrophages.
- macrophages induced by IGF 25-91 were co-cultured with T cells after LPS pre-stimulation. It was found that macrophages treated with IGF 25-91 could significantly promote the differentiation of Treg, and the promotion depended on the high expression of PD-L1. Further, the studies showed that macrophages treated with IGF 25-91 could also be directly used to treat autoreactive encephalomyelitis and inflammatory bowel disease. During the treatment process, the infusion of these macrophages also promoted the increase of Treg proportion in mice.
- IGF 25-91 affects the expression of PD-L1 in macrophages
- control cells a detailed comparison was made between macrophages treated with IGF 25-91 and control cells. It was found that macrophages treated with IGF 25-91 can significantly change the status of glucose metabolism pathway of macrophages, making them more apt to oxidative phosphorylation metabolic pathway. When blocking macrophages mitochondrial oxidative phosphorylation, the high expression of PD-L1 and the ability to promote Treg differentiation induced by insulin-like growth factor ⁇ 2 in macrophages also disappeared. These studies illustrate that IGF 25-91 endows macrophages with the ability of promoting Treg generation and treating autoimmune diseases by changing the metabolism tendencies of macrophages.
- IGF 25-91 plays a therapeutic role in multiple sclerosis and inflammatory bowel disease by inducing immunosuppressive macrophages and up-regulating regulatory T cells. Macrophages treated with IGF 25-91 may play a therapeutic role in autoimmune diseases. In addition, the targeted regulation of aerobic glycolysis and oxidative phosphorylation in macrophages can induce the production of immunosuppressant macrophages and play a role in the treatment of various autoimmune diseases.
- This invention provides a pharmaceutical composition for (i) promoting PD-L1 expression and/or (ii) inhibiting IL-1 ⁇ expression in macrophages. It contains a safe and effective dose of IGF-2 (or its active fragments) or contains IGF-2 treated macrophages.
- the pharmaceutical composition of the invention can be used for (i) promoting PD-L1 expression and/or (ii) inhibiting IL-1 ⁇ expression in macrophages.
- the pharmaceutical composition can be used together with other autoimmune diseases therapies.
- the pharmaceutical composition of the invention can also contain macrophage scavenger which is an agent for removing macrophages or inhibiting macrophage migration.
- macrophage scavenger which is an agent for removing macrophages or inhibiting macrophage migration.
- the invention also provides a medicine kit comprising:
- a first container which contains an active ingredient (i) IGF-2 or a medicine containing the active ingredient (a);
- a second container which contains an active ingredients
- macrophage scavenger or a medicine containing the active ingredient (b), wherein the macrophage scavenger is agent for removing macrophage or inhibiting macrophage migration
- the pharmaceutical composition of the invention contains a safe and effective dose of IGF-2 and a pharmaceutically acceptable carrier.
- the carrier includes (not limited to): saline, buffer solution, glucose, water, glycerin, alcohol, powder and the combination thereof.
- the formulation of the medicine should be compatible with the method of administration.
- the pharmaceutical composition of the invention can be prepared in the form of an injection, for example, by a conventional method using saline or an aqueous solution containing glucose and other adjuvants.
- Pharmaceutical compositions such as tablets and capsules may be prepared by conventional methods.
- Pharmaceutical composition such as injection, solution, tablet and capsule should be manufactured under sterile conditions.
- the pharmaceutical composition of the invention can also be made into powder for atomizing inhalation.
- the dose of the active ingredient is an effective dose, such as about 1 ⁇ g/kg-50 mg/kg, about 5 ⁇ g/kg-10 mg/kg, about 10 ⁇ g/kg-5 mg/kg of body weight per day.
- the pharmaceutical composition can be administered together with other therapies.
- the pharmaceutical composition of the invention can be administered to a subject (such as human and non-human mammal) in routine manner.
- a subject such as human and non-human mammal
- the representative way for administration includes (but not limit to): oral administration, injection and aerosol inhalation.
- the pharmaceutical composition should be administered to a mammal in a safe and effective dose.
- the safe and effective dose is usually at least 10 ⁇ g/kg of body weight and no more than 50 mg/kg of body weight under most conditions.
- the preferred dose should range from 10 ⁇ g/kg to 20 mg/kg of body weight.
- the exact dose should be determined according to the administration route and the patient health conditions which are all within the expertise of a skilled physician.
- IGF-2 and the active fragment thereof can (i) promote PD-L1 expression and/or (ii) inhibit IL-1 ⁇ expression in macrophages.
- Macrophages treated with IGF-2 or the active fragment thereof can promote Treg differentiation and inhibit Th1 cell and/or Th17 cell differentiation so as to treat autoimmune diseases.
- Combination therapy of IGF-2 or active fragment thereof with macrophage scavenger can be used for treating autoimmune diseases.
- Emulsification of antigen Two glass syringes were connected through a three-way tube, an equal volume of antigen solution (300 ⁇ g MOG in 100 ⁇ L PBS) and 100 ⁇ L of complete Freund's adjuvant were added into the syringes, and the bubbles in the syringes were removed and the syringes were pushed back and forth to obtain an emulsion. After about 500 pushes, the push resistance would gradually increase indicating the ingredients were fully mixed into an emulsified state.
- pertussis toxin PT solution: pertussis toxin was dissolve in PBS at a working concentration of 1 ng/ ⁇ L and 200 ⁇ L per mouse was injected through the tail vein.
- insulin-like growth factor 2 was used for treatment via intraperitoneal injection at a dose of 5 ng/mouse everyday.
- the saline treated group served as a positive control.
- the spinal cord was removed from EAE mice and washed with PBS.
- the spinal cord was mechanically ground on a 70 ⁇ m pore size cell screen to obtain a single cell suspension.
- the obtained cell suspension was centrifuged, and the cells were resuspended in 30% percoll, and an equal volume of 70% percoll solution was gently added to the bottom. Centrifugation was carried out at 2000 rpm for 20 minutes at room temperature under zero acceleration. After centrifugation, cells were aspirated from the liquid junction layer of high-low density and washed twice with PBS to obtain lymphocytes.
- mice After the EAE mice were sacrificed, the spleen of the mice was removed and a single cell suspension was obtained.
- the splenocytes were plated in a U-bottom 96-well plate at a number of 3-5 ⁇ 10 5 per well, and MOG was added to 20 ug/ml.
- H3 labeled thymidine was added. After 6 hours, the well plate was freeze-thawed repeatedly and then vacuum-adsorbed onto a special filter. The scintillation solution was added and then detected on the machine.
- Dextran sodium sulfate was formulated into a solution at a mass to volume ratio of 2.5:100, filtered with a 22 ⁇ m strainer to ensure sterility, and sealed with a parafilm.
- insulin-like growth factor-2 was injected intraperitoneally at a dose of 50 ng/mouse everyday.
- the saline treated group served as a positive control.
- the colon was removed from the IBD mice, the feces were removed and washed with PBS. Then the colon was cut into 2 cm sections and rinsed twice in HBSS (1 mM DTT and 5 mM EDTA) under conditions of 250 rpm for 20 min at 37° C. The washed colon tissue was cut as much as possible with scissors and added into HBSS containing DNAase I, dispase and type VIII collegenase under the conditions of 250 rpm for 30 min at 37° C. The obtained cell suspension was centrifuged, and the cells were resuspended in 40% percoll, and an equal volume of 80% percoll solution was gently added to the bottom. Centrifugation was carried out at 2000 rpm for 20 minutes at room temperature under zero acceleration. After centrifugation, cells were aspirated from the liquid junction layer of high-low density and washed twice with PBS to obtain lymphocytes.
- Cells were implanted on the hippocampal test plate at a density of 1 ⁇ 10 5 cells per well.
- XF culture was supplemented with 10 mM glucose, 2 mM glutamine and 2 mM pyruvate to prepare a test medium.
- the cells were washed twice with the test medium before testing on the machine.
- Metabolic inhibitors were prepared using test medium: 1 ⁇ M oligomycin, 0.75 ⁇ M FCCP, 100 ⁇ M rotenone and 1 ⁇ M Mantimycin.
- the consumption rate of oxygen and the concentration of extracellular hydrogen ion at basic status and under drug stimulation conditions were measured.
- the instrument used was Extracellular flux analyzer.
- the preparation process of bone marrow derived macrophages was as follows: mouse bone marrow was blown out with 1 ml syringe. After being full dispersed, the cells were centrifuged according to the condition of 400 g for 5 min. The supernatant was discarded, the cells were blown into single cell suspension, and the cells were laid on an uncoated culture dish in DMEM/F12 completely medium (containing 10% FBS, 20% L929 supernatant, 100 U/ml Penicillin, 100 U/ml Streptomycin, 2 mm L—Glutamine). At the fourth day of culture, 5 ml solution was added, and the cells were further cultured for 6 days, and mature macrophages could be obtained. IGF-2 stimulation was added on Day 1, 3 and 5, respectively.
- peritoneal derived macrophages The preparation process of peritoneal derived macrophages was as follows: 2 ml of 4% thioglycollate solution was intraperitoneally injected into 8-12 weeks aged C57BL/6 mice, cytokines or PBS were intraperitoneally injected daily every day. On the third day, mice were sacrificed. Macrophages in abdominal cavity were blown out by using a 10 ml syringe with 10 ml volume of PBS. After centrifugation, the cells were scattered to form a single cell suspension, and were then inoculated in an uncoated cell dish or a 6-well plate, for following experiments.
- Macrophages derived from mature bone marrow or peritoneal were stimulated with LPS for 24 hours.
- the stimulation solution was aspirated and cells were washed with PBS for three times to fully remove the residual LPS.
- the macrophages (2.5 ⁇ 10 5 ) and selected CD4 + CD62L + T cells (1 ⁇ 10 6 ) were laid on a 96-well plate. After 72 hours of co-culture, the cells were blown out for flow cytometry staining and analysis.
- mice purchased from slake Shanghai experimental animal center of Chinese academy of sciences
- a high-fat diet for 20 weeks, starting from the 5th week.
- mice were starved overnight, and 1 g glucose/kg body weight was intraperitoneally injected. At different time points, a drop of tail venous blood of each mouse was siphoned into the blood glucose test paper, and blood glucose was measured with a blood glucose meter.
- mice were starved overnight for about 16 hours, and 0.75U insulin/kg body weight was intraperitoneally injected.
- a drop of tail venous blood of each mouse was siphoned into the blood glucose test paper, and blood glucose was measured with a blood glucose meter, and accurate timing was conducted with a timer.
- IGF 25-91 When treated with IGF 25-91 in mice induced EAE, it was observed that IGF 25-91 effectively alleviated the pathogenesis and severity of EAE, which was manifested by decreased clinical score, decreased number of infiltrating mononuclear cells in the spinal cord, and decreased proliferation of MOG-specific T cells in EAE mice ( FIGS. 1 a - c ). Meanwhile, flow cytometry analysis showed that the use of IGF 25-91 could effectively reduce the proportions of Th1 and Th17 in the spinal cord of EAE mice and increase the proportion of Treg ( FIGS. 1 d - g ).
- IGF 25-91 can be used in the treatment of EAE and can influence the ratio of different T cell subsets and the gene expression of macrophages in diseased mice.
- Macrophages Treated with IGF 25-91 can Promote the Production of Treg and Treat EAE
- the treated macrophages (including bone marrow derived macrophages and peritoneal derived macrophages) were used in the treatment of EAE.
- the results showed that macrophages pretreated with IGF 25-91 could effectively alleviate the clinical scores of EAE, and promote the proportion of Treg in the spleen of EAE mice ( FIGS. 3 f - g ; FIGS. 5 a - c ).
- IGF 25-91 When tracking the oxygen consumption and acid production in macrophages, it was found that IGF 25-91 could effectively improve the efficiency of the oxygen consumption in macrophages, and at the same time reduce the acid production in macrophages in the background state ( FIGS. 6 d - f ).This suggests that IGF 25-91 can tilt macrophage metabolism toward the oxidative phosphorylation pathway.
- IGF 25-91 and IGF 25-91 Pre-Treated Macrophages are Effective in Treating Inflammatory Bowel Diseases (IBD).
- IGF 25-91 was used to treat IBD, an autoimmune disease dominated by the innate immune system.
- the weight loss of IBD mice was alleviated, colon injury and infiltration of monocytes in the colon were significantly reduced ( FIGS. 7 a - c ).
- Flow cytometry was used to analyze T cell populations and macrophage gene expression, and it was found that IGF 25-91 could increase Treg percentages in the colon and mesenteric lymph nodes ( FIGS. 7 d - e ; FIGS. 8 a - b ).
- IGF 25-91 can significantly inhibit inflammatory diseases, such as the above-mentioned multiple sclerosis and inflammatory bowel diseases. Moreover, this effect is closely related to the IGF 25-91 regulation on macrophages which are reprogrammed into macrophages with immunosuppressive function, thus inhibiting over-strong inflammatory response.
- inflammatory diseases such as the above-mentioned multiple sclerosis and inflammatory bowel diseases.
- this effect is closely related to the IGF 25-91 regulation on macrophages which are reprogrammed into macrophages with immunosuppressive function, thus inhibiting over-strong inflammatory response.
- systemic and local inflammation is often accompanied by a large amount of proinflammatory macrophage infiltration, and the macrophage infiltration in inflammatory site often depends on an influx of peripheral monocytes and its evolution into proinflammatory macrophages. Therefore, we investigated whether a combination of clearance of resident proinflammatory macrophages and the reprogramming function of IGF 25-91 on macrophages can optimize the treatment
- mice in different experimental groups received IGF 25-91 , Clodronate liposome (for removing macrophage) or a combined injection of IGF 25-91 and Clodronate liposome.
- the progress of EAE in mice was observed. It was found that single injection of IGF 25-91 and Clodronate liposome could significantly inhibit the progress of EAE and had an effective therapeutic effect compared with the control group. More importantly, a combined injection of IGF 25-91 and Clodronate liposome had a more significant therapeutic effect on EAE compared with other groups ( FIG. 10 ). Therefore, the combination therapy of IGF 25-91 and macrophage scavenger has a more optimized effect in the treatment of inflammatory diseases by reprogramming cells into macrophages with immunosuppressive function.
- IGF 25-91 Pre-Treated Macrophages can be Used to Treat Obesity-Induced Insulin Resistance.
- mice were fed with high fat diet for 20 weeks and then injected with PBS, macrophages (5 ⁇ 10 6 ) or IGF 25-91 pre-treated macrophages (5 ⁇ 10 6 ). Two weeks after the treatment, glucose tolerance test and insulin tolerance test were conducted, and glucose changes in each group were detected. The results showed that IGF 25-91 pre-treated macrophages could significant improve the ability of glucose tolerance in the insulin resistance mice ( FIGS. 13A and 13B ). These results demonstrated that IGF 25-91 pre-treated macrophages were effective in treating insulin resistance and diabetes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
- This invention relates to the field of biological medicine, and in particular to a pharmaceutical composition containing insulin-like growth factor-2 and use thereof.
- Macrophages are specialized immune cells distributed in all parts of the body. They remove the senescence cells, certain cells that cannot be recognized as their own, cell debris and so on through phagocytosis. As the professional antigen presenting cells, macrophages initiate the immune responses of unsensitized T cells and trigger the inflammatory response. However, inflammatory cytokines expressed by macrophages such as TNFα and IL-1 also play important roles in the pathogenesis of many autoimmune diseases. Removal of pathogenic macrophages has been shown to significantly inhibit autoimmune encephalomyelitis and inflammatory bowel diseases. In addition to their pro-inflammatory properties, macrophages can be regulated by different circumstances factors into cells with immunosuppressive effect, such as macrophages marked by expressing IL-1β , Arginase I, etc, as well as macrophages with immunosuppressive function which are formed by different immune stimuli in the evolution process of monocytes to macrophages, thereby directly or indirectly regulating the body's immune response. It has been reported that spermidine treated macrophages are able to powerfully treat autoimmune diseases, indicating that macrophages with immunosuppressive effect have significant therapeutic effects in autoimmune diseases.
- Currently, there is limited understanding on the application of macrophages to treat autoimmune diseases. New therapeutic strategies employing the plasticity of macrophages for autoimmune diseases are urgently need in the art.
- The present invention provides a composition containing insulin-like growth factor-2 and the uses thereof.
- The first aspect of the invention provides a use of insulin-like growth factor-2 (IGF-2) to prepare a composition (including a chemical preparation and a pharmaceutical composition) to (i) increase PD-L1 expression in macrophage and/or (ii) inhibit IL-1β expression in macrophage.
- In another preferred embodiment, the IGF-2 includes full length IGF-2 and an active fragment of IGF-2.
- In another preferred embodiment, the active fragment of IGF-2 is an active fragment having amino acids from
position 25 to position 91 of IGF-2. - In another preferred embodiment, the active fragment of IGF-2 is the amino acid sequence of
position 25 to position 91 of IGF-2. - In another preferred embodiment, the IGF-2 is from human and non-human mammals.
- In another preferred embodiment, the amino acid sequence of the IGF-2 is shown in SEQ ID NO.:1.
- In another preferred embodiment, the pharmaceutical composition is also used for one or more of the purposes selected from the group consisting of:
- (a) promoting oxidative phosphorylation metabolic pathway in macrophage;
- (b) promoting differentiation of regulatory T cell;
- (c) inhibiting differentiation of Th1 cell and/or Th17 cell; and
- (d) treating autoimmune disease.
- In another preferred embodiment, the autoimmune disease is selected from the group consisting of multiple sclerosis, inflammatory bowel disease, autoimmune encephalomyelitis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, insulin resistance, diabetes, liver cirrhosis or a combination thereof.
- In another preferred embodiment, the insulin resistance or the diabetes is obesity-induced insulin resistance or obesity-induced diabetes.
- In another preferred embodiment, the pharmaceutical composition comprises (a) IGF-2; and (b) a pharmaceutically acceptable carrier.
- In another preferred embodiment, the pharmaceutical composition comprises 0.001-99 wt %, preferred 0.1-90 wt %, and more preferred 1-80% IGF-2, based on the total weight of the pharmaceutical composition.
- In another preferred embodiment, the pharmaceutical composition comprises macrophage scavenger, and the scavenger is a formulation for removing macrophage or inhibiting macrophage migration.
- In another preferred embodiment, the pharmaceutical composition comprises agonist of PD-L1.
- In another preferred embodiment, the pharmaceutical composition is liquid or lyophilized formulation.
- In another preferred embodiment, the pharmaceutical composition is an injection formulation.
- The second aspect of the invention provides a use of macrophage treated with insulin-like growth factor-2 (IGF-2) for preparing a pharmaceutical composition for one or more of the purposes selected from the group consisting of:
- (b) promoting differentiation of regulatory T cell;
- (c) inhibiting differentiation of Th1 cell and/or Th17 cell; and
- (d) treating autoimmune disease.
- In another preferred embodiment, macrophage is cultured in the presence of IGF-2 to obtain the macrophage treated with the IGF-2.
- The third aspect of the invention provides a pharmaceutical composition comprising (a) IGF-2 or the active fragment thereof (such as active fragment having amino acids from
position 25 to position 91), (b) optionally, macrophage scavenger, (c) optionally, PD-L1 promoter, and (d) a pharmaceutically acceptable carrier. - In another preferred embodiment, at least one of the components (b) and (c) is present.
- In another preferred embodiment, the macrophage scavenger is an agent for removing macrophage or inhibiting macrophage migration.
- In another preferred embodiment, the formulation of the pharmaceutical composition is an injection formulation, sustained release formulation or topical formulation.
- In another preferred embodiment, the pharmaceutical composition is used for one or more of the purposes selected from the group consisting of:
- (a) promoting PD-L1 expression in macrophage;
- (b) inhibiting IL-1β expression in macrophage;
- (c) promoting differentiation of regulatory T cell;
- (d) inhibiting differentiation of Th1 cell and/or Th17 cell; and
- (e) treating autoimmune disease.
- In another preferred embodiment, the pharmaceutical composition comprises macrophage scavenger which depletes macrophage or suppresses macrophage migration.
- In another preferred embodiment, the macrophage scavenger is selected from the group consisting of: CCR2 inhibitor (to inhibit macrophage migration), clodronate disodium liposome (to remove macrophage) and a combination thereof.
- In another preferred embodiment, if the pharmaceutical composition comprises component (a), component (b) and component (c), the mass ratio of component (a): component (b): component (c) is (1-100): (1-100): (1-100).
- In another preferred embodiment, if the pharmaceutical composition comprises component (a) and component (b), the mass ratio of component (a): component (b) is (1-100): (1-100).
- In another preferred embodiment, if the pharmaceutical composition comprises component (a) and component (c), the mass ratio of component (a): component (c) is (1-100): (1-100).
- In another preferred embodiment, the ratio (mg: mg) of IGF-2 active fragment having amino acids from
position 25 to position 91 to macrophage scavenger ranges from 1:100 to 100:1, preferably, from 1:20 to 20:1. - In another preferred embodiment, the total content of IGF-2 active fragment having amino acids from
position 25 to position 91 and macrophage scavenger is 1 to 99 wt % of the pharmaceutical composition, preferably, 5 to 90wt % of the total pharmaceutical composition. - The fourth aspect of the invention provides a pharmaceutical composition comprising (a1) IGF-2 inhibitor, (b1) optionally, macrophage agonist, (c1) optionally, PD-L1 inhibitor, and (d1) a pharmaceutically acceptable carrier.
- In another preferred embodiment, at least one of the components (b1) and (c1) is present.
- In another preferred embodiment, the PD-L1 inhibitor includes PD-L1 antibodies.
- In another preferred embodiment, if the pharmaceutical composition comprises component (a1), component (b1) and component (c1), the mass ratio of component (a1): component (b1): component (c1) is (1-100): (1-100): (1-100).
- In another preferred embodiment, if the pharmaceutical composition comprises component (a1) and component (b1), the mass ratio of component (a1): component (b1) is (1-100): (1-100).
- In another preferred embodiment, if the pharmaceutical composition comprises component (a1) and component (c1), the mass ratio of component (a1): component (c1) is (1-100): (1-100).
- The fifth aspect of the invention provides a macrophage pre-treated with IGF-2.
- In another preferred embodiment, in the macrophage, the PD-L1 expression is up-regulated and/or (ii) the IL-1β expression is down-regulated.
- In another preferred embodiment, the up-regulation referred to that the ratio of PD-L1 expression quantity in treated macrophage (M1) to PD-L1 expression quantity in untreated macrophage (M0) M1/M0 is ≥1.5, preferably, M1/M0≥2.0, more preferably,
M 1/M0≥3.0. In another preferred embodiment, the down-regulation referred to that the ratio of IL-1β expression quantity in untreated macrophage (N0) to IL-1β expression quantity in treated macrophage (N1) N0/N1 is ≥1.5, preferably, N0/N1≥2.0, more preferably, N0/N1≥3.0. - In another preferred embodiment, the treatment includes exposing macrophage to IGF-2 or IGF-2 active fragment for a period of time (such as 0.1-24 hours).
- The sixth aspect of the invention provides a pharmaceutical composition for regulating T cell differentiation, which comprises IGF-2 treated macrophage and a pharmaceutically acceptable carrier.
- In another preferred embodiment, the regulating T cell differentiation referred to (b) promoting differentiation of regulatory T cell; and/or (c) inhibiting differentiation of Th1 and/or Th17 cell.
- In another preferred embodiment, the pharmaceutical composition is used for treating autoimmune disease.
- The seventh aspect of the invention provides a non-therapeutic method for (i) promoting PD-L1 expression and/or (ii) inhibiting IL-1β expression in macrophage, which comprises the following steps:
- (a) culturing macrophage in the presence of IGF-2 to (i) enhance PD-L1 expression and/or (ii) inhibit IL-1β expression.
- In another preferred embodiment, the concentration of IGF-2 is 1 ng/ml-100 μg/ml, preferably, 3 ng/ml-1 μg/ml, and more preferably, 5 ng/ml-50 ng/ml.
- The eighth aspect of the invention provides a polypeptide with a sequence of
position 25 to position 91 of SEQ ID NO.: 1. - The ninth aspect of the invention provides a method for (i) enhancing PD-L1 expression and/or (ii) inhibiting IL-1β expression, which comprises the following steps:
- (a) administrating IGF-2 to a subject in need.
- In another preferred embodiment, the subject includes human and nonhuman mammal.
- In another preferred embodiment, the dose of IGF-2 administered is 1 ng-1 mg/kg, preferably, 100 ng-100μg/kg, and more preferably, 1-10 μg/kg.
- In another preferred embodiment, the method further comprises the steps of:
- (b) applying macrophage scavenger, which is an agent for removing macrophage or inhibiting macrophage migration, to a subject in need.
- In another preferred embodiment, the dose and frequency of macrophage scavenger are administered in a conventional manner.
- In another preferred embodiment, the administration includes administrating simultaneously or successively.
- The tenth aspect of the invention provides a medicine kit, which contains:
- (i) a first container, which contains an active ingredient (a) IGF-2 or a medicine containing the active ingredient (a);
- (ii) a second container, which contains an active ingredients (b) macrophage scavenger or a medicine containing the active ingredient (b), wherein the macrophage scavenger is an agent for removing macrophage or inhibiting macrophage migration, and
- (iii) a specification describing the combined administration of the active ingredient (a) and the active ingredient (b) for treating an autoimmune disease.
- In another preferred embodiment, the medicine in the first container or the second container is a formulation containing one single active ingredient (a) or a formulation containing one single active ingredient (b).
- The eleventh aspect of the invention provides a use of the pharmaceutical composition in the third aspect and the medicine kit in the tenth aspect in preparation of a medicine for treating an autoimmune disease.
- It should be understood that in the present invention, the technical features specifically described above and below (such as the Examples) can be combined with each other, thereby constituting a new or preferred technical solution, which needs not be described one by one, due to space limitations.
-
FIG. 1 shows that insulin-like growth factor 2 (IGF-2) is effective in treating EAE. -
FIG. 1a shows that IGF-2 can effectively alleviate the progress and degree of EAE. -
FIG. 1b shows that IGF-2 can effectively inhibit mononuclear cell infiltration in the central nervous system. -
FIG. 1c shows that IGF-2 can effectively inhibit MOG specific T cell proliferation in EAE mice. -
FIG. 1d, 1e, 1f, and 1g show that IGF-2 can effectively inhibit the cell proportion of Th1 and Th17 in EAE mice and promote the proportion of Treg. -
FIG. 1h shows that IGF-2 does not directly effect the differentiation of Th1/Th17/Treg. -
FIG. 1i and 1j show that IGF-2 promotes PD-L1 expression and inhibits IL-1β expression in the CD11b+F4/80+ macrophage in the spinal cord of EAE mice. -
FIG. 2 shows that insulin-like growth factor-2 (IGF-2) can induce anti-inflammatory macrophages. -
FIG. 2a shows that IGF-2 does not affect the number of macrophages in the spinal cord of EAE mice. -
FIG. 2b shows that IGF-2 does not affect the number of macrophages in the spleen of EAE mice. -
FIG. 2c shows that IGF-2 inhibits the expression level of IL-1β in CD11b+F4/80+ macrophages in the spleen of EAE mice. -
FIG. 2d shows that IGF-2 promotes the expression level of PD-L1 in CD11b+F4/80+ macrophages in the spinal cord of EAE mice. -
FIG. 2e shows that IGF-2 does not affect the expression levels of MHC-I, MHC-II, CD80, and CD86 in thioglycollate medium-induced peritoneal macrophages. -
FIG. 2f shows that IGF-2 does not affect the expression levels of TNF-α, IL-6 and TGF-β in peritoneal macrophages under lipopolysaccharide (LPS) stimulation and thioglycollate medium-induction. -
FIG. 2g shows that IGF-2 inhibits the mRNA levels of inducible nitric oxide synthase (iNOS) and the production of nitrite regulated by the enzyme, in the peritoneal macrophages under lipopolysaccharide (LPS) stimulation and thioglycollate medium-induction. -
FIG. 3 shows that insulin-like growth factor-2 (IGF-2) treated macrophages are effective in treating EAE. -
FIG. 3a shows that after IGF-2 pretreatment, under 100 ng/ml LPS stimulation, the ability of peritoneal macrophages induced by thioglycollate medium to express messenger RNA and precursor proteins of IL-1β is significantly decreased. -
FIG. 3b shows that after IGF-2 pretreatment, under 100 ng/ml LPS stimulation, the IL-1β protein level secreted by peritoneal macrophages induced by thioglycollate medium is significantly decreased.. -
FIG. 3c shows that after IGF-2 pretreatment, under 100 ng/ml LPS stimulation, the PD-L1 protein level expressed by peritoneal macrophages induced by thioglycollate medium is significantly increased. -
FIGS. 3d and 3e show that IGF-2 treated macrophages are able to promote Treg differentiation depend on PD-L1. -
FIG. 3f shows that IGF-2 treated macrophages significantly inhibits EAE. -
FIG. 3g shows that IGF-2 treated macrophages can effectively promote the proportion of Tregs in EAE mice. -
FIG. 4 shows that bone marrow derived macrophages treated with insulin-like growth factor-2 (IGF-2) to promote the differentiation ability of regulatory T cell. -
FIG. 4a shows that bone marrow derived macrophages treated with IGF-2 express significant higher level of PD-L1 under LPS stimulation. -
FIGS. 4b and 4c show that bone marrow derived macrophages treated with IGF-2 promote Treg through PD-L1. -
FIG. 4d shows no change in the expression levels of MHC-I, MHC-II, CD80, and CD86 in bone marrow derived macrophages treated with IGF-2. -
FIG. 5 shows that bone marrow derived macrophages treated with insulin-like growth factor-2 (IGF-2) are effectively in alleviating experimental autoimmune encephalomyelitis (EAE) and inflammatory bowel disease (IBD). -
FIG. 5a shows that bone marrow derived macrophages treated with IGF-2 are effective in treating EAE. -
FIGS. 5b and 5c show that bone marrow derived macrophages treated with IGF-2 effectively increase the proportion of Treg in EAE mice. -
FIG. 5d shows that bone marrow derived macrophages treated with IGF-2 relieved weight loss in IBD mice. Macrophages treated with IGF-2 shows the ability to effectively treat IBD. -
FIG. 5e shows that bone marrow derived macrophages treated with IGF-2 can effectively prolong the survival time of mice with IBD. -
FIGS. 5f and 5g show that bone marrow derived macrophages treated with IGF-2 effectively increase the proportion of Treg cells in spleen in the IBD mice. -
FIG. 6 shows that insulin-like factor-2 (IGF-2) affects the anti-inflammatory prosperities of macrophages through regulating their glycometabolism. -
FIG. 6a shows that glucose consumption was significantly reduced in macrophages after IGF-2 treated. -
FIG. 6b shows that lactic acid accumulation was significantly reduced in macrophages after IGF-2 treated. -
FIG. 6c shows that NAD+/NADH ratio was significantly reduced in macrophages after IGF-2 treated. -
FIG. 6d shows that the ability of oxidative phosphorylation and oxygen consumption was significantly increased in macrophages after IGF-2 treated. -
FIG. 6e shows that extracellular acidification was significantly reduced in macrophages after IGF-2 treated. -
FIG. 6f shows that macrophages preferred to conduct oxidative phosphorylation after IGF-2 treated. -
FIG. 6g shows that oligomycin could inhibit the improvement of PD-L1 expression in peritoneal macrophages treated with IGF-2 and induced by thioglycollate medium. -
FIG. 6h shows that oligomycin inhibits oxidative phosphorylation, and demonstrates that macrophages treated with IGF-2 have high expression of PD-L1 depended on aerobic respiration and the ability to promote the production of Treg. -
FIG. 7 shows that insulin-like growth facor-2 (IGF-2) and IGF-2 treated macrophages are effective in treating experimental bowel disease. -
FIG. 7a shows that IGF-2 protects IBD mice from body weight loss. -
FIG. 7b shows that IBD mice received IGF-2 treatment have significant longer colon length. -
FIG. 7c shows that numbers of mononuclear cells infiltration significantly decrease in colon after IGF-2 treatment. -
FIGS. 7d and 7e show that the proportion of Treg cells in the lamina propria of colon significantly increase in the IBD mice after IGF-2 treatment. -
FIG. 7f shows that the expression of PD-L1 significantly increases in CD11b+F4/80+ macrophages in the lamina propria of colon of the IBD mice after IGF-2 treatment. -
FIG. 7g shows that the expression level of IL-1β significantly decrease in CD11b+F4/80+ macrophages in the lamina propria of colon of the IBD mice after IGF-2 treatment. -
FIG. 7h shows that IGF-2 treated macrophage relieves the body weight loss of experimental bowel disease mice. -
FIG. 7i shows that IGF-2 treated macrophage effectively prolongs the survival time of the IBD mice. -
FIG. 7j shows that the proportion of Treg cells in spleen significantly increase in the IBD mice injected with IGF-2 treated macrophage. -
FIG. 8 shows that insulin-like growth factor-2 (IGF-2) regulates immune response in the spleen and peritoneal lymph nodes of inflammatory bowel disease (IBD) mice. -
FIGS. 8a and 8b show that IGF-2 significantly up regulates the proportion of Tregs in the peritoneal lymph nodes of mice with IBD. -
FIG. 8c shows that IGF-2 does not affect the proportion of spleen macrophages in mice with IBD. -
FIG. 8d shows that IGF-2 upregulates the proportion of CD11b+F4/80+ macrophages in the colon lamina propria of mice with IBD. -
FIG. 8e shows that IGF-2 significantly downregulates the expression level of IL-1β in spleen macrophages in mice with IBD. -
FIG. 8f shows that IGF-2 significantly up regulates the expression level of PD-L1 in spleen macrophages in mice with IBD. -
FIG. 9 shows that peritoneal macrophages treated with insulin-like growth factor-2 (IGF-2) and induced by thioglycollate medium can upregulate Tregs in lamina propria of colon and peritoneal lymph nodes of IBD mice. -
FIG. 9a shows that IGF-2 treated macrophages can significantly increase the proportion of Tregs in peritoneal lymph nodes of IBD mice. -
FIG. 9b shows that IGF-2 pre-treated macrophages can significantly increase the proportion of Tregs in lamina propria of colon of IBD mice. -
FIG. 10 shows that separate injection of insulin-like growth factor-2 (IGF-2) and clodronate liposome can significantly inhibit the progress of EAE and play an effective therapeutic role when compared with that of control mice group. Importantly, combined injection of IGF-2 and clodronate liposome has significantly better therapeutic effects on EAE than other groups. -
FIG. 11 shows the tertiary structure of insulin-like growth factor-2 (IGF-2). -
FIG. 12 shows the key binding sites of insulin-like growth factor-2 (IGF-2) to the receptor. -
FIG. 13A shows the results of glucose tolerance test. -
FIG. 13B shows the results of insulin tolerance test. - IGF-2 applied in the reference and description of
FIGS. 1-13 is active fragment of IGF-2 containing amino acids fromposition 25 to position 91. (IGF25-91) - After extensive and thorough studies, the inventors have firstly established a pharmaceutical composition containing insulin-like growth factor-2 and use thereof. This invention provides the use of IGF-2 and its active fragment for preparing a pharmaceutical composition. The pharmaceutical composition can be used for (i) enhancing PD-L1 expression and/or (ii) inhibiting IL-1β expression in macrophages. The invention also provides a pharmaceutical composition containing insulin-like growth factor-2 as an active ingredient.
- Specifically, in the invention, it is found that both insulin-like growth factor-2 (IGF-2) and the active fragment having amino acids from
position 25 to position 91 of IGF-2 (IGF25-91) show significant therapeutic effects in the treatment of animal models of multiple sclerosis and colitis (experimental autoimmune encephalomyelitis and DSS-induced inflammatory bowel diseases), and can significantly inhibit the progression of the disease and the tissue damage and inflammatory infiltration in corresponding site. More importantly, IGF25-91 indirectly upregulates regulatory T cells (Treg) by inducing macrophages with low IL-1 expression and high PD-L1 expression, thereby promoting the recovery of autoimmune diseases. IGF25-91 mainly promotes the reprogramming of macrophages into macrophages with immunosuppressive function by affecting the aerobic glycolysis and oxidative phosphorylation pathways of macrophages, and such macrophages treated with IGF25-91 have a very significant effect on the treatment of autoimmune diseases. Based on the therapeutic effect of IGF25-91 on autoimmune diseases, the present invention clarifies the regulatory mechanism of IGF25-91 on macrophages, and it is found that IGF25-91 induces the application potential of macrophages with immunosuppressive function in the treatment of autoimmune diseases, thus forming a new technique for macrophage immunotherapy. - Insulin-Like Growth Factor-2
- Insulin-like growth factor-2 (IGF-2) is a growth factor mainly synthesized in the liver and is abundantly present in the blood. IGF-2 has anti-apoptosis, growth regulation, insulin-like and mitotic functions. IGF-2 precursor protein, which is translated from mRNA, consists of 180 amino acids, as shown in the sequence SEQ ID NO.: 1 (mgipmgksmlvlltflafascciaayrpset lcggelvdtlqfvcgdrgfyfsrpasrvsrrsrgiveeccfrscdlalletycatpakserdvstpptvlpdnfprypvgkffqydtwkqst qrlrrglpallrarrghvlakeleafreakrhrplialptqdpahggappemasnrk); The active form produced after modification after translation consists of 67 amino acids, as shown in the sequence SEQ ID NO.: 2 (ayrpseticggelvdtlqfvcgdrgfyfsrpasrvsrrsrgiveeccfrscdlalletycatpakse). The tertiary structure of IGF-2 is composed of three α-helixes and two β-sheets as shown in
FIG. 11 , wherein amino acids 11G-21C forms a helix, 25G-27Y forms the first sheet, the second helix is 42I-49R, the third helix is 53L-58T and the second sheet is 59Y-61A. It is predicted that T16 and F19 on the first helix and L63 on the third helix are sites where IGF-2 binds to receptor of IGF-2 as shown inFIG. 12 . - At present, it is generally believed that IGF-2 has an important role in embryo development and can promote embryo development and organ formation. It has also been reported to be linked to memory and reproduction, and studies in genetically deficient mice have shown that lack of insulin-like growth factor-2 signaling can lead to poor brain development.
- The present invention has found that administration of IGF-2 or active fragment having the amino acids sequence from
position 25 to position 91 of IGF-2 (IGF25-91) alone can effectively treat experimental autoimmune encephalomyelitis or inflammatory bowel disease, which are two autoimmune diseases. In the lesion site, such as the spinal cord or colon of the diseased mice, the proportion of regulatory T cells in the IGF25-91 treatment group was significantly increased, and the proportions of TH1 and TH17 cells were significantly decreased. - However, when the in vitro T cell differentiation system was used to verify the effect of IGF25-91 on T cell differentiation, it was found that IGF25-91 could not directly affect the efficiency of T cell differentiation into Th1, Th17 and Treg. These studies suggest that IGF25-91 has an indirect effect on the proportion change of T cell subsets. Significant changes in the macrophage phenotype were also observed when insulin-like growth factor-2 was used to treat autoimmune diseases. It was found in the study that the expression of IL-1β in macrophages at the injury site of mice treated with IGF25-91 was significantly decreased, while the expression of PD-L1 was significantly increased, suggesting that IGF25-91 played a role in inhibiting autoimmune diseases through promoting the proportion of macrophages with anti-inflammatory effects.
- It is found in the study that IGF25-91 does not directly induce the expression of anti-inflammatory genes in macrophages. However, the bone marrow or enterocoelia derived mature macrophages treated with IGF25-91 exhibit significantly decrease of IL-1β expression and significantly increase of PD-L1 expression in response to lipopolysaccharide stimulation. Macrophages play an important role in the occurrence and development of autoimmune diseases. A series of studies have shown that macrophages can exert strong proinflammatory ability under the stimulation of inflammatory factors such as interferon and lipopolysaccharide, which aggravate the process of autoimmune diseases. Studies have shown that insulin-like growth factor-2 alters the response of macrophages to inflammatory factors, and macrophages overexpress the anti-inflammatory molecule PD-L1 under the condition of proinflammatory stimulation. Therefore, the treatment of autoimmune diseases by IGF25-91 is likely to be achieved by reprogramming macrophages.
- In order to clarify the role of macrophages treated with IGF25-91 in regulating Treg, macrophages induced by IGF25-91 were co-cultured with T cells after LPS pre-stimulation. It was found that macrophages treated with IGF25-91 could significantly promote the differentiation of Treg, and the promotion depended on the high expression of PD-L1. Further, the studies showed that macrophages treated with IGF25-91 could also be directly used to treat autoreactive encephalomyelitis and inflammatory bowel disease. During the treatment process, the infusion of these macrophages also promoted the increase of Treg proportion in mice.
- In order to further explain how IGF25-91 affects the expression of PD-L1 in macrophages, a detailed comparison was made between macrophages treated with IGF25-91 and control cells. It was found that macrophages treated with IGF25-91 can significantly change the status of glucose metabolism pathway of macrophages, making them more apt to oxidative phosphorylation metabolic pathway. When blocking macrophages mitochondrial oxidative phosphorylation, the high expression of PD-L1 and the ability to promote Treg differentiation induced by insulin-like growth factor −2 in macrophages also disappeared. These studies illustrate that IGF25-91 endows macrophages with the ability of promoting Treg generation and treating autoimmune diseases by changing the metabolism tendencies of macrophages.
- In conclusion, IGF25-91 plays a therapeutic role in multiple sclerosis and inflammatory bowel disease by inducing immunosuppressive macrophages and up-regulating regulatory T cells. Macrophages treated with IGF25-91 may play a therapeutic role in autoimmune diseases. In addition, the targeted regulation of aerobic glycolysis and oxidative phosphorylation in macrophages can induce the production of immunosuppressant macrophages and play a role in the treatment of various autoimmune diseases.
- Pharmaceutical Composition and Instructions
- This invention provides a pharmaceutical composition for (i) promoting PD-L1 expression and/or (ii) inhibiting IL-1β expression in macrophages. It contains a safe and effective dose of IGF-2 (or its active fragments) or contains IGF-2 treated macrophages.
- The pharmaceutical composition of the invention can be used for (i) promoting PD-L1 expression and/or (ii) inhibiting IL-1β expression in macrophages. The pharmaceutical composition can be used together with other autoimmune diseases therapies.
- The pharmaceutical composition of the invention can also contain macrophage scavenger which is an agent for removing macrophages or inhibiting macrophage migration. Experiments showed that the combination therapy of IGF-225-91 and macrophage scavenger played a more optimized role in the treatment of inflammatory diseases by reprogramming macrophages with immunosuppressive function.
- The invention also provides a medicine kit comprising:
- (i) a first container which contains an active ingredient (a) IGF-2 or a medicine containing the active ingredient (a);
- (ii) a second container which contains an active ingredients (b) macrophage scavenger or a medicine containing the active ingredient (b), wherein the macrophage scavenger is agent for removing macrophage or inhibiting macrophage migration, and
- (iii) an specification describing a combined administration of the active ingredient (a) and the active ingredient (b) for treating autoimmune diseases.
- The pharmaceutical composition of the invention contains a safe and effective dose of IGF-2 and a pharmaceutically acceptable carrier. The carrier includes (not limited to): saline, buffer solution, glucose, water, glycerin, alcohol, powder and the combination thereof. The formulation of the medicine should be compatible with the method of administration.
- The pharmaceutical composition of the invention can be prepared in the form of an injection, for example, by a conventional method using saline or an aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as tablets and capsules may be prepared by conventional methods. Pharmaceutical composition such as injection, solution, tablet and capsule should be manufactured under sterile conditions. The pharmaceutical composition of the invention can also be made into powder for atomizing inhalation. The dose of the active ingredient is an effective dose, such as about 1 μg/kg-50 mg/kg, about 5 μg/kg-10 mg/kg, about 10 μg/kg-5 mg/kg of body weight per day. The pharmaceutical composition can be administered together with other therapies.
- The pharmaceutical composition of the invention can be administered to a subject (such as human and non-human mammal) in routine manner. The representative way for administration includes (but not limit to): oral administration, injection and aerosol inhalation.
- The pharmaceutical composition should be administered to a mammal in a safe and effective dose. The safe and effective dose is usually at least 10 μg/kg of body weight and no more than 50 mg/kg of body weight under most conditions. The preferred dose should range from 10 μg/kg to 20 mg/kg of body weight. The exact dose should be determined according to the administration route and the patient health conditions which are all within the expertise of a skilled physician.
- The Main Advantages of the Present Invention Includes:
- (a) IGF-2 and the active fragment thereof (from
position 25 to position 91) can (i) promote PD-L1 expression and/or (ii) inhibit IL-1β expression in macrophages. - (b) Macrophages treated with IGF-2 or the active fragment thereof can promote Treg differentiation and inhibit Th1 cell and/or Th17 cell differentiation so as to treat autoimmune diseases.
- (c) Combination therapy of IGF-2 or active fragment thereof with macrophage scavenger can be used for treating autoimmune diseases.
- The present invention will be further illustrated below with reference to the specific examples. It should be understood that these examples are only to illustrate the invention but not to limit the scope of the invention. For the experimental methods in the following examples the specific conditions of which are not specifically indicated, they are performed under routine conditions, or as instructed by the manufacturers, unless otherwise specified. Unless indicated otherwise, parts and percentage are weight parts and weight percentage.
- Materials and Methods
- Establishment and Treatment of Experimental Autoreactive Encephalomyelitis EAE Model
- (1) Preparation Before Experiment
- Preparation of complete freund's adjuvant: heat inactivated mycobacterium tuberculosis (purchased from sigma) was added into incomplete freund's adjuvant until the final concentration reached 5 mg/ml, and the solution were thoroughly mixed before use.
- Emulsification of antigen: Two glass syringes were connected through a three-way tube, an equal volume of antigen solution (300 μg MOG in 100 μL PBS) and 100 μL of complete Freund's adjuvant were added into the syringes, and the bubbles in the syringes were removed and the syringes were pushed back and forth to obtain an emulsion. After about 500 pushes, the push resistance would gradually increase indicating the ingredients were fully mixed into an emulsified state.
- Preparation of pertussis toxin (PT) solution: pertussis toxin was dissolve in PBS at a working concentration of 1 ng/μL and 200 μL per mouse was injected through the tail vein.
- (2) Establishment and Treatment of EAE Model
- On
day - On
day - From the ninth day, insulin-
like growth factor 2 was used for treatment via intraperitoneal injection at a dose of 5 ng/mouse everyday. The saline treated group served as a positive control. - When macrophages were used for treatment, 5×106 macrophages were injected intraperitoneally on
Day - (3) Clinical Scoring of EAE
- 0: clinically normal; 0.5: tail drooping at the tip; 1: whole tail paralysis; 2: hind legs weakness; 3: one hind limb paralysis; 4. both hind limbs paralysis; 5: died.
- 2. Extraction of Lymphocytes from Spinal Cord
- The spinal cord was removed from EAE mice and washed with PBS. The spinal cord was mechanically ground on a 70 μm pore size cell screen to obtain a single cell suspension. The obtained cell suspension was centrifuged, and the cells were resuspended in 30% percoll, and an equal volume of 70% percoll solution was gently added to the bottom. Centrifugation was carried out at 2000 rpm for 20 minutes at room temperature under zero acceleration. After centrifugation, cells were aspirated from the liquid junction layer of high-low density and washed twice with PBS to obtain lymphocytes.
- 3. In Vitro Proliferation Experiment of Splenocytes
- After the EAE mice were sacrificed, the spleen of the mice was removed and a single cell suspension was obtained. The splenocytes were plated in a U-bottom 96-well plate at a number of 3-5×105 per well, and MOG was added to 20 ug/ml.
- After incubation at 37° C. for 72 hours in an incubator, H3 labeled thymidine was added. After 6 hours, the well plate was freeze-thawed repeatedly and then vacuum-adsorbed onto a special filter. The scintillation solution was added and then detected on the machine.
- 4. Establishment and Treatment of Inflammatory Bowel Disease IBD Model
- Dextran sodium sulfate (DSS) was formulated into a solution at a mass to volume ratio of 2.5:100, filtered with a 22 μm strainer to ensure sterility, and sealed with a parafilm.
- 8-10 weeks aged C57/BL6 female mice (purchased from Slack Shanghai Laboratory Animal Center of the Chinese Academy of Sciences) were selected and used. Dextran sodium sulfate solution was used to replace the drinking water to induce the model. The mice weight and feces were observed every day. The dextran sulfate sodium solution was changed or added every other day.
- From the day of model induction, insulin-like growth factor-2 was injected intraperitoneally at a dose of 50 ng/mouse everyday. The saline treated group served as a positive control.
- When macrophages were used for treatment, 5×107 macrophages were injected intraperitoneally on
Day - 5. Extraction of Lymphocyte from Colon Tissue
- The colon was removed from the IBD mice, the feces were removed and washed with PBS. Then the colon was cut into 2 cm sections and rinsed twice in HBSS (1 mM DTT and 5 mM EDTA) under conditions of 250 rpm for 20 min at 37° C. The washed colon tissue was cut as much as possible with scissors and added into HBSS containing DNAase I, dispase and type VIII collegenase under the conditions of 250 rpm for 30 min at 37° C. The obtained cell suspension was centrifuged, and the cells were resuspended in 40% percoll, and an equal volume of 80% percoll solution was gently added to the bottom. Centrifugation was carried out at 2000 rpm for 20 minutes at room temperature under zero acceleration. After centrifugation, cells were aspirated from the liquid junction layer of high-low density and washed twice with PBS to obtain lymphocytes.
- 6. Hippocampal Test
- Cells were implanted on the hippocampal test plate at a density of 1×105 cells per well. XF culture was supplemented with 10 mM glucose, 2 mM glutamine and 2 mM pyruvate to prepare a test medium. The cells were washed twice with the test medium before testing on the machine. Metabolic inhibitors were prepared using test medium: 1 μM oligomycin, 0.75 μM FCCP, 100 μM rotenone and 1 μM Mantimycin. The consumption rate of oxygen and the concentration of extracellular hydrogen ion at basic status and under drug stimulation conditions were measured. The instrument used was Extracellular flux analyzer.
- 7. Preparation and Treatment of Macrophages
- The preparation process of bone marrow derived macrophages was as follows: mouse bone marrow was blown out with 1 ml syringe. After being full dispersed, the cells were centrifuged according to the condition of 400 g for 5 min. The supernatant was discarded, the cells were blown into single cell suspension, and the cells were laid on an uncoated culture dish in DMEM/F12 completely medium (containing 10% FBS, 20% L929 supernatant, 100 U/ml Penicillin, 100 U/ml Streptomycin, 2 mm L—Glutamine). At the fourth day of culture, 5 ml solution was added, and the cells were further cultured for 6 days, and mature macrophages could be obtained. IGF-2 stimulation was added on
Day - The preparation process of peritoneal derived macrophages was as follows: 2 ml of 4% thioglycollate solution was intraperitoneally injected into 8-12 weeks aged C57BL/6 mice, cytokines or PBS were intraperitoneally injected daily every day. On the third day, mice were sacrificed. Macrophages in abdominal cavity were blown out by using a 10 ml syringe with 10 ml volume of PBS. After centrifugation, the cells were scattered to form a single cell suspension, and were then inoculated in an uncoated cell dish or a 6-well plate, for following experiments.
- 8. Co-Culture System of Macrophages and Naïve T Cells
- Macrophages derived from mature bone marrow or peritoneal were stimulated with LPS for 24 hours. The stimulation solution was aspirated and cells were washed with PBS for three times to fully remove the residual LPS. Then, the macrophages (2.5×105) and selected CD4+CD62L+ T cells (1×106) were laid on a 96-well plate. After 72 hours of co-culture, the cells were blown out for flow cytometry staining and analysis.
- 9. Establish Obesity Modeling by High-Fat Diet Induction
- C57/BL6 mice (purchased from slake Shanghai experimental animal center of Chinese academy of sciences) were fed with a high-fat diet for 20 weeks, starting from the 5th week.
- 10. Glucose Tolerance Test
- The mice were starved overnight, and 1 g glucose/kg body weight was intraperitoneally injected. At different time points, a drop of tail venous blood of each mouse was siphoned into the blood glucose test paper, and blood glucose was measured with a blood glucose meter.
- 11. Insulin Tolerance Test
- The mice were starved overnight for about 16 hours, and 0.75U insulin/kg body weight was intraperitoneally injected. At different time points, a drop of tail venous blood of each mouse was siphoned into the blood glucose test paper, and blood glucose was measured with a blood glucose meter, and accurate timing was conducted with a timer.
- IGF25-91 can Treat Experimental Autoimmune Encephalomyelitis (EAE) Depending on its Regulation of Gene Expression in Macrophages
- When treated with IGF25-91 in mice induced EAE, it was observed that IGF25-91 effectively alleviated the pathogenesis and severity of EAE, which was manifested by decreased clinical score, decreased number of infiltrating mononuclear cells in the spinal cord, and decreased proliferation of MOG-specific T cells in EAE mice (
FIGS. 1a-c ). Meanwhile, flow cytometry analysis showed that the use of IGF25-91 could effectively reduce the proportions of Th1 and Th17 in the spinal cord of EAE mice and increase the proportion of Treg (FIGS. 1d-g ). However, when the inventor added IGF25-91 directly into an in vitro differentiation system of T cells, it was found that the differentiation efficiency of T cells into Th1, Th17 and Treg was not affected, suggesting that IGF25-91 had an indirect effect on T cells (FIG. 1h ). - When flow cytometry instrument was used to analyze immune cells in EAE mice, it was also found that although the use of IGF25-91 did not affect the percentage of macrophages in the spinal cord and spleen in EAE disease mice (
FIGS. 2a-b ), it could significantly affect the gene expression in macrophages, which was shown as significantly decreased expression of IL-1β and significantly increased expression of PD-L1 in macrophages (FIGS. 1i-j ;FIGS. 2c-d ). In conclusion, IGF25-91 can be used in the treatment of EAE and can influence the ratio of different T cell subsets and the gene expression of macrophages in diseased mice. - Macrophages Treated with IGF25-91 can Promote the Production of Treg and Treat EAE
- In order to further study the effect of IGF25-91 on macrophages, two classical methods were used to prepare macrophages for research. One was inducing peritoneal macrophages with thioglycollate, and the other was differentiating macrophages using bone marrow cells stimulated by L929 cell culture supernatant. It was found that after receiving IGF25-91 treatment during the differentiation of macrophages, there was no significant change in the expression of co-stimulating molecules (CD80, CD86, MHC I, MHC II), TNF-α, IL-6, and TGF-β in peritoneal macrophages or bone marrow derived macrophages (
FIGS. 2e-f ;FIG. 4d ). However, after lipopolysaccharide stimulation, compared with control macrophages, the expression of IL-1β was significantly decreased, while the expression of PD-L1 was significantly increased in insulin-like growth factor-2 treated macrophages, which was quite consistent with the observed phenomenon in vivo (FIGS. 3a-c ). In order to study the effect of macrophages treated with IGF25-91 on Treg differentiation, macrophages and T cells were co-cultured, and anti-CD3, anti-CD28 and TGF-β required for Treg differentiation were added into the culture system. The results showed that, compared with normal macrophages, macrophages treated with IGF25-91 (including bone marrow derived macrophages and peritoneal derived macrophages) could promote Treg production more effectively after LPS pre-stimulation. At the same time, PD-L1 played a crucial role in this process, because once a neutralizing antibody against PD-L1 was used, the Treg-promoting capacity of macrophages treated with IGF25-91 was inhibited (FIGS. 3d-e ;FIGS. 4a-c ). - In order to further validate the immune regulation ability of macrophages treated with IGF25-91, the treated macrophages (including bone marrow derived macrophages and peritoneal derived macrophages) were used in the treatment of EAE. The results showed that macrophages pretreated with IGF25-91 could effectively alleviate the clinical scores of EAE, and promote the proportion of Treg in the spleen of EAE mice (
FIGS. 3f-g ;FIGS. 5a-c ). - IGF25-91 Affected Gene Expression of Macrophages through Elevating Oxidative Phosphorylation Metabolic Pathway
- To investigate the regulatory mechanism of IGF25-91 on macrophages, the properties of IGF25-91 pre-treated macrophages and control macrophages were compared and it was found that both glucose consumption and lactate accumulation were decreased in IGF25-91 pre-treated macrophages (
FIGS. 6a-b ). NAD+/NADH ratio in macrophages was also reduced after IGF25-91 treatment (FIG. 6c ), suggesting that IGF25-91 could regulate the metabolic pathways of glycolysis and oxidative phosphorylation in macrophages. When tracking the oxygen consumption and acid production in macrophages, it was found that IGF25-91 could effectively improve the efficiency of the oxygen consumption in macrophages, and at the same time reduce the acid production in macrophages in the background state (FIGS. 6d-f ).This suggests that IGF25-91 can tilt macrophage metabolism toward the oxidative phosphorylation pathway. - In order to confirm that the metabolic state of oxidative phosphorylation was the basis for the high expression of PD-L1 in macrophages and the promotion of Treg differentiation, oligomycin (an inhibitor of oxidative phosphorylation process) was used. It was found that once the oxidative phosphorylation was blocked, the high expression of PD-L1 in macrophages and the ability to promote the differentiation of Treg caused by IGF25-91 disappeared (
FIGS. 6g-h ). This suggests that the high expression of PD-L1 in macrophages and the ability to promote the differentiation of Treg induced by IGF25-91 depend on the metabolic mode of oxidative phosphorylation. - IGF25-91 and IGF25-91 Pre-Treated Macrophages are Effective in Treating Inflammatory Bowel Diseases (IBD).
- To further validate the therapeutic effects of IGF25-91 on autoimmune diseases and the regulation of macrophages, IGF25-91 was used to treat IBD, an autoimmune disease dominated by the innate immune system. After treatment with IGF25-91, the weight loss of IBD mice was alleviated, colon injury and infiltration of monocytes in the colon were significantly reduced (
FIGS. 7a-c ). Flow cytometry was used to analyze T cell populations and macrophage gene expression, and it was found that IGF25-91 could increase Treg percentages in the colon and mesenteric lymph nodes (FIGS. 7d-e ;FIGS. 8a-b ). Meanwhile, the decreased expression of IL-1β and the increased expression of PD-L1 in macrophages were observed in the colon and spleen (FIGS. 7f-g ;FIGS. 8c-f ). Moreover, IGF25-91 pre-treated macrophages could be administered directly in the treatment of IBD to alleviate body weight loss and improve the survival rate of IBD mice (FIGS. 5d-e ;FIGS. 7h-i ). IGF25-91 pre-treated macrophages also increase Treg percentages in the spleen, peyer's patches and mesenteric lymph nodes (FIGS. 5f-g ;FIGS. 7h-j ). - IGF25-91 and Macrophage Scavenger are more Effective in Treating Inflammatory Diseases
- IGF25-91 can significantly inhibit inflammatory diseases, such as the above-mentioned multiple sclerosis and inflammatory bowel diseases. Moreover, this effect is closely related to the IGF25-91 regulation on macrophages which are reprogrammed into macrophages with immunosuppressive function, thus inhibiting over-strong inflammatory response. However, when inflammatory disease occurs, systemic and local inflammation is often accompanied by a large amount of proinflammatory macrophage infiltration, and the macrophage infiltration in inflammatory site often depends on an influx of peripheral monocytes and its evolution into proinflammatory macrophages. Therefore, we investigated whether a combination of clearance of resident proinflammatory macrophages and the reprogramming function of IGF25-91 on macrophages can optimize the treatment of inflammatory disease. On the 9th, 11th, and 13th day of EAE induction, mice in different experimental groups received IGF25-91, Clodronate liposome (for removing macrophage) or a combined injection of IGF25-91 and Clodronate liposome. The progress of EAE in mice was observed. It was found that single injection of IGF25-91 and Clodronate liposome could significantly inhibit the progress of EAE and had an effective therapeutic effect compared with the control group. More importantly, a combined injection of IGF25-91 and Clodronate liposome had a more significant therapeutic effect on EAE compared with other groups (
FIG. 10 ). Therefore, the combination therapy of IGF25-91 and macrophage scavenger has a more optimized effect in the treatment of inflammatory diseases by reprogramming cells into macrophages with immunosuppressive function. - IGF25-91 Pre-Treated Macrophages can be Used to Treat Obesity-Induced Insulin Resistance.
- Mice were fed with high fat diet for 20 weeks and then injected with PBS, macrophages (5×106) or IGF25-91 pre-treated macrophages (5×106). Two weeks after the treatment, glucose tolerance test and insulin tolerance test were conducted, and glucose changes in each group were detected. The results showed that IGF25-91 pre-treated macrophages could significant improve the ability of glucose tolerance in the insulin resistance mice (
FIGS. 13A and 13B ). These results demonstrated that IGF25-91 pre-treated macrophages were effective in treating insulin resistance and diabetes. - All references mentioned in the present invention are incorporated herein by reference, as each of them is individually cited herein by reference. Further, it should be understood that, after reading the above contents, the skilled person can make various modifications or amendments to the present invention. All these equivalents also fall into the scope defined by the pending claims of the subject application.
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611073977.1A CN108114271B (en) | 2016-11-29 | 2016-11-29 | Pharmaceutical composition containing insulin-like growth factor-2 and application thereof |
CN201611073977.1 | 2016-11-29 | ||
PCT/CN2017/113341 WO2018099363A1 (en) | 2016-11-29 | 2017-11-28 | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/113341 A-371-Of-International WO2018099363A1 (en) | 2016-11-29 | 2017-11-28 | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/300,286 Division US20230364201A1 (en) | 2016-11-29 | 2023-04-13 | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190381147A1 true US20190381147A1 (en) | 2019-12-19 |
Family
ID=62226867
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/464,902 Abandoned US20190381147A1 (en) | 2016-11-29 | 2017-11-28 | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof |
US18/300,286 Pending US20230364201A1 (en) | 2016-11-29 | 2023-04-13 | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/300,286 Pending US20230364201A1 (en) | 2016-11-29 | 2023-04-13 | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof |
Country Status (5)
Country | Link |
---|---|
US (2) | US20190381147A1 (en) |
EP (1) | EP3549598A4 (en) |
CN (2) | CN108114271B (en) |
AU (1) | AU2017370226B2 (en) |
WO (1) | WO2018099363A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112546228A (en) * | 2019-09-10 | 2021-03-26 | 中国科学院上海营养与健康研究所 | Use of non-IGF 1R-binding substances for preventing and/or treating inflammatory diseases |
KR20230090336A (en) * | 2020-10-13 | 2023-06-21 | 베타바이브 리미티드 | Methods and compounds for treating diabetes and related metabolic diseases |
CN112472798A (en) * | 2020-12-09 | 2021-03-12 | 南华大学附属第一医院 | Application of insulin-like growth factor 2 recombinant protein in preparation of medicine for treating ulcerative colitis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ260309A (en) * | 1992-06-08 | 1997-07-27 | Pharmacia Ab Substituted For K | Use of 1gf-2 for prevention or treatment of nutritional or gastrointestinal disorders and promoting neonatal growth |
EP1313499B1 (en) * | 2000-08-29 | 2010-04-07 | Aurogen Incorporated | Method for treating the central nervous system by administration of igf structural analogs |
WO2003049761A1 (en) * | 2000-12-08 | 2003-06-19 | Neuronz Limited | Use of insuline-like growth factor-i for promoting remyelination of axons |
US20040138116A1 (en) * | 2002-08-30 | 2004-07-15 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
CN101466398A (en) * | 2006-06-09 | 2009-06-24 | 诺瓦提斯公司 | Stabilized insulin-like growth factor polypeptides |
CN102830223A (en) * | 2012-08-14 | 2012-12-19 | 四川汇宇制药有限公司 | Screening method for drugs used for treating neoplastic diseases in mammals |
US20140255413A1 (en) * | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
-
2016
- 2016-11-29 CN CN201611073977.1A patent/CN108114271B/en active Active
-
2017
- 2017-11-28 AU AU2017370226A patent/AU2017370226B2/en active Active
- 2017-11-28 WO PCT/CN2017/113341 patent/WO2018099363A1/en unknown
- 2017-11-28 CN CN201780048982.3A patent/CN109562145B/en active Active
- 2017-11-28 US US16/464,902 patent/US20190381147A1/en not_active Abandoned
- 2017-11-28 EP EP17876571.5A patent/EP3549598A4/en active Pending
-
2023
- 2023-04-13 US US18/300,286 patent/US20230364201A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018099363A1 (en) | 2018-06-07 |
AU2017370226B2 (en) | 2021-05-20 |
AU2017370226A1 (en) | 2019-08-01 |
CN109562145A (en) | 2019-04-02 |
US20230364201A1 (en) | 2023-11-16 |
CN109562145B (en) | 2023-01-06 |
CN108114271B (en) | 2021-07-02 |
CN108114271A (en) | 2018-06-05 |
EP3549598A4 (en) | 2020-06-03 |
EP3549598A1 (en) | 2019-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230364201A1 (en) | Pharmaceutical composition containing insulin-like growth factor-2 and use thereof | |
Bai et al. | Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis | |
KR101723265B1 (en) | Mesenchymal stem cells treated mTOR/STAT3 signaling inhibitor having immuno-modulating activity and cell therapeutic agent for preventing or treating immune disease | |
Xiang et al. | Kinsenoside attenuates liver fibro-inflammation by suppressing dendritic cells via the PI3K-AKT-FoxO1 pathway | |
Ohshima et al. | Systemic transplantation of allogenic fetal membrane-derived mesenchymal stem cells suppresses Th1 and Th17 T cell responses in experimental autoimmune myocarditis | |
KR102213890B1 (en) | A method for inducing transdifferentiation of immune cell based on exosome | |
US20180200301A1 (en) | Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof | |
US10519441B2 (en) | Use of miRNA-214 inhibitor in inhibiting regulatory cells | |
WO2015172659A1 (en) | Uses of il-17 in enhancing immune-suppression function of mesenchymal stem cells | |
JP2016138092A (en) | Mesenchymal stem cell for treating hepatic disease | |
WO2016119308A1 (en) | Antitumour preparation and preparation method thereof | |
Wei et al. | IL‐38 attenuates myocardial ischemia–reperfusion injury by inhibiting macrophage inflammation | |
US10071119B2 (en) | Application of mesenchymal stem cells in prophylaxis or treatment of stress response-induced weakened immunity | |
CN109432128A (en) | Application of the dental pulp mescenchymal stem cell in curing psoriasis | |
WO2017193862A1 (en) | Fats as melanoma immunotherapy target and application thereof | |
Wu et al. | Protosappanin A protects against experimental autoimmune myocarditis, and induces metabolically reprogrammed tolerogenic DCs | |
WO2017063196A1 (en) | C-rel-specific sirna and application thereof for treating autoimmune psoriasis | |
CN106591370A (en) | Virus vector for treating autoimmune related diseases and diabetes, construction method and applications thereof | |
Ishida et al. | Regulation of experimental autoimmune uveoretinitis by anti-delta-like ligand 4 monoclonal antibody | |
CN115120701A (en) | Depression improving composition and preparation method and application thereof | |
CN107569678B (en) | Application of liraglutide in preparation of medicine for treating acute and chronic transplant rejection | |
He et al. | Amygdalin ameliorates alopecia areata on C3H/HeJ mice by inhibiting inflammation through JAK2/STAT3 pathway | |
CN112704687A (en) | Preparation containing mesenchymal stem cells and application thereof in psoriasis treatment | |
CN109432116A (en) | Astragaloside III is preparing the purposes in immunotherapy of tumors drug | |
US9833473B2 (en) | Tolerogenic dendritic cells for treating myocardial infarction and manufacturing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHI, YUFANG;WANG, YING;DU, LIMING;AND OTHERS;SIGNING DATES FROM 20190710 TO 20190714;REEL/FRAME:049904/0712 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: SHANGHAI INSTITUTE OF NUTRITION AND HEALTH, CHINESE ACADEMY OF SCIENCES, CHINA Free format text: CHANGE OF NAME;ASSIGNOR:SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES;REEL/FRAME:055114/0210 Effective date: 20200410 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |